IPC 2025
Athens, Greece, 24 - 26 Jun 2025
We are looking forward to supporting the 18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health in June 2025.
Dr Ross Lindsay will be presenting on, ‘Breath-taking analysis of microbial metabolites,’ on Tuesday 24th June at 15.30.
This three-day event will provide the opportunity to explore the latest advancements in probiotics, prebiotics, and gut microbiota with leading scientists, researchers, and industry experts. IPC2025 will showcase cutting-edge research, clinical insights, and emerging trends shaping the future of microbiome science.
We’re excited to attend, connect with key innovators, and engage in discussions that will drive progress in this rapidly evolving field.
If you are interested in learning more about the work Owlstone Medical is doing, please get in touch to meet with us at the conference.
Meet the Team
Dr Ross Lindsay
Dr Ross Lindsay, from our Clinical Biomarker Sciences Department, is looking forward to attending IPC 2025, where he will deliver a talk on the power of breath analysis for monitoring the microbiome.
Ross works across our clinical studies and strategic initiatives, with the aim of delivering brilliantly designed and exciting breath studies in multiple fields of research. He is currently very excited about the potential of breath as a technology to investigate the microbiome, and feels that the unique volatile products of bacterial metabolism offer a fantastic opportunity to investigate the state of the microfloral environment and its implications for human health.
By background, Ross is a metabolic biology expert with extensive experience applying “omics” technologies to research and development successes. Following completion of his PhD and postdoc at the University of Cambridge, where amongst other achievements he pioneered the application of novel metabolomics techniques to cardiometabolic disease studies, he joined AstraZeneca. There, he developed treatments and disease understanding for a diverse range of conditions including obesity, diabetes, fatty liver disease and kidney disease. Ross has also worked in the biotech building space, assembling and enabling teams to bring the next generation of exciting technology to the public.
Dr Ben Constant
Dr Ben Constant is a Business Development Executive at Owlstone Medical, where he is dedicated to advancing breath biomarker research.
Ben completed his undergraduate studies in Biomedical Sciences at the University of Sheffield, before pursuing a PhD at the University of Cambridge under the supervision of Dr Wei Li in the Department of Medicine. His doctoral research focused on elucidating the mechanisms of action of a novel pharmaceutical treatment for obesity.
Ben has a diverse background in the medical technology sector. He previously worked at Ortho Clinical Diagnostics, where he contributed to the development of a diagnostic test for heart attacks. Additionally, he has served as a technical consultant, assisting MedTech innovators in bringing their cutting-edge technologies to market.
In his current role, Ben is passionate about collaborating with leading scientists across Europe and Asia, helping them explore how breath biomarkers can enhance their research and clinical outcomes.
